CGI1746 910232-84-7
Product Description
.cp_wz table {border-top: 1px solid #ccc;border-left:1px solid #ccc; } .cp_wz table td{border-right: 1px solid #ccc; border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;} .cp_wz table th {border-right: 1px solid #ccc;border-bottom: 1px solid #ccc; padding: 5px 0px 0px 5px;}
Molecular Weight:
579.69 CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.
Biological Activity
CGI1746 is specific for Btk, with ∼1,000-fold selectivity over Tec and
Src family kinases. In an ATP-free competition binding assay, the
dissociation constant for Btk is 1.5 nM. CGI1746 inhibits Btk activity
in a new binding mode that stabilizes an inactive nonphosphorylated
enzyme conformation. CGI1746 inhibits both auto- and
transphosphorylation steps necessary for enzyme activation. CGI1746
completely inhibits anti-IgM–induced murine and human B cell
proliferation, with IC50s of 134 nM and 42 nM, respectively, but had no
effect on anti-CD3- and anti-CD28–induced T cell proliferation. CGI1746
potently inhibits the proliferation of CD27+IgG+ B cells isolated from
the tonsils of four human donors with an average IC50 of 112 nM. In
macrophages, CGI1746 abolishes FcγRIII-induced TNFα, IL-1β and IL-6
production. CGI1746 potently inhibits TNFα, IL-1β and, to a lesser
extent, IL-6 (three- to eight-fold higher IC50) production in human
monocytes stimulated with immobilized or soluble immune complexes.
CGI1746 abrogates B cell–dependent arthritis. CGI1746 treatment (100
mg/kg, s.c, twice-daily dosing) results in significant inhibition (97%)
of overall clinical arthritis scores.
CGI1746 treatment substantially reduces TNFα, IL-1β and IL-6, as well as
MCP1 and MIP-1α on both the mRNA and protein level in the passive
anti-collagen II antibody–induced arthritis (CAIA) model.
CGI1746 shows comparable efficacy to TNFα blockade and significantly
reduces clinical scores, as well as joint inflammation, in mice or rats
with established arthritis.
Protocol(Only for Reference)
Kinase Assay: [1]
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Chemical Information
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 910232-84-7. We are ready to answer your questions on packaging, logistics, certification or any other aspects about CGI1746 910232-84-7、910232-84-7 CGI1746. If these products fail to match your need, please contact us and we would like to provide relevant information.
Molecular Weight:
579.69 CGI1746 is a potent and highly selective small-molecule inhibitor of the Btk with IC50 of 1.9 nM.
Biological Activity
CGI1746 is specific for Btk, with ∼1,000-fold selectivity over Tec and
Src family kinases. In an ATP-free competition binding assay, the
dissociation constant for Btk is 1.5 nM. CGI1746 inhibits Btk activity
in a new binding mode that stabilizes an inactive nonphosphorylated
enzyme conformation. CGI1746 inhibits both auto- and
transphosphorylation steps necessary for enzyme activation. CGI1746
completely inhibits anti-IgM–induced murine and human B cell
proliferation, with IC50s of 134 nM and 42 nM, respectively, but had no
effect on anti-CD3- and anti-CD28–induced T cell proliferation. CGI1746
potently inhibits the proliferation of CD27+IgG+ B cells isolated from
the tonsils of four human donors with an average IC50 of 112 nM. In
macrophages, CGI1746 abolishes FcγRIII-induced TNFα, IL-1β and IL-6
production. CGI1746 potently inhibits TNFα, IL-1β and, to a lesser
extent, IL-6 (three- to eight-fold higher IC50) production in human
monocytes stimulated with immobilized or soluble immune complexes.
CGI1746 abrogates B cell–dependent arthritis. CGI1746 treatment (100
mg/kg, s.c, twice-daily dosing) results in significant inhibition (97%)
of overall clinical arthritis scores.
CGI1746 treatment substantially reduces TNFα, IL-1β and IL-6, as well as
MCP1 and MIP-1α on both the mRNA and protein level in the passive
anti-collagen II antibody–induced arthritis (CAIA) model.
CGI1746 shows comparable efficacy to TNFα blockade and significantly
reduces clinical scores, as well as joint inflammation, in mice or rats
with established arthritis.
Protocol(Only for Reference)
Kinase Assay: [1]
Lanthascreen assay | Lanthascreen assay is performed at Km for ATP (10 μM) with human full-length Btk (C-terminal V5-His6 expressed in Sf9 cells) and quantified on an EnVision. |
---|
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species | Baboon | Dog | Monkey | Rabbit | Guinea pig | Rat | Hamster | Mouse |
Weight (kg) | 12 | 10 | 3 | 1.8 | 0.4 | 0.15 | 0.08 | 0.02 |
Body Surface Area (m2) | 0.6 | 0.5 | 0.24 | 0.15 | 0.05 | 0.025 | 0.02 | 0.007 |
Km factor | 20 | 20 | 12 | 12 | 8 | 6 | 5 | 3 |
Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
Animal A Km |
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
Rat dose (mg/kg) = mouse dose (22.4 mg/kg) × | mouse Km(3) | = 11.2 mg/kg |
rat Km(6) |
Chemical Information
Molecular Weight (MW) | 579.69 |
---|---|
Formula | C34H37N5O4 |
CAS No. | 910232-84-7 |
Storage | 3 years -20℃Powder |
---|---|
6 months-80℃in solvent (DMSO, water, etc.) | |
Synonyms | N/A |
Solubility (25°C) * | In vitro | DMSO | 100 mg/mL (172.5 mM) |
---|---|---|---|
Water | <1 mg/mL ( | ||
Ethanol | 100 mg/mL (172.5 mM) | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Chemical Name | N-[3-[4,5-dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxopyrazinyl]-2-methylphenyl]-4-(1,1-dimethylethyl)-benzamide |
---|
Molarity Calculator
Dilution Calculator
Molecular Weight Calculator
Contact us if you need more details on 910232-84-7. We are ready to answer your questions on packaging, logistics, certification or any other aspects about CGI1746 910232-84-7、910232-84-7 CGI1746. If these products fail to match your need, please contact us and we would like to provide relevant information.
Product Categories : Angiogenesis > BTK Inhibitor
Other Products
Hot Products
Astragaloside AChlortetracycline HCl 64-72-2Paclitaxel 33069-62-4Dexamethasone Acetate 1177-87-3Dinaciclib (SCH727965) 779353-01-4CHIR-124 405168-58-3Ro3280 1062243-51-9TAME 901-47-3CCG-1423 285986-88-110058-F4 403811-55-2Dabigatran (BIBR 953) 211914-51-1H 89 2HCl 130964-39-5T0901317 293754-55-9Aprepitant 170729-80-3Turofexorate Isopropyl (XL335) 629664-81-9BMS-378806 357263-13-9